🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the battle against superbug strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to major issues, including infertility. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Global Access

As per data detailed in a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The study involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to register and commercialise the drug in numerous developing nations.

Medical professionals on the front lines have voiced optimism. The availability of a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as essential to lessen the impact of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.